Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,175 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Oropharynx Cancer, HPV-Related Carcinoma
Interventions
Radiation, Platinum based chemotherapy
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, Irinotecan, 5-FU, Gemcitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia
Interventions
Lirilumab, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
adjuvant therapy, diagnostic thoracoscopy, therapeutic thoracoscopy, video-assisted surgery, radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2005
U.S. locations
13
States / cities
Denver, Colorado • Des Moines, Iowa • Boston, Massachusetts + 8 more
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, 3'-deoxy-3'-[18F]fluorothymidine, pharmacological study, Mibefradil
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Biospecimen Collection, Computed Tomography, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Phase 2 Interventional Results available

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

NCT01270724
Conditions
CNS Germ Cell Tumor
Interventions
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more
Conditions
Breast Cancer
Interventions
Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
368
States / cities
Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more
Conditions
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
Interventions
XmAb20717
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Conditions
Lung Cancer
Interventions
Cs-131 brachytherapy seeds
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia, Solid Tumors
Interventions
Clinimacs Cell Separation System, conditioning chemotherapy, DLI
Device · Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Months to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Human Papilloma Virus
Interventions
Zinc Sulfate, Placebo (Gelatin Tablet)
Dietary Supplement · Other
Lead sponsor
Corewell Health West
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Renal Cell Carcinoma
Interventions
Atezolizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
45
States / cities
Scottsdale, Arizona • Duarte, California • Lancaster, California + 37 more
Conditions
Adenoma, Pleomorphic, Mixed Salivary Gland Tumor, Salivary Gland Tumor, Mixed, Syringoma, Chondroid
Interventions
Radiation, Panitumumab
Radiation · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
27
States / cities
Steubenville, Ohio • Beaver, Pennsylvania • Clairton, Pennsylvania + 13 more
Conditions
Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
Interventions
Best Practice, Biospecimen Collection, Bone Metastases Treatment, Computed Tomography, Conventional Radiotherapy, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Stereotactic Body Radiation Therapy
Other · Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
625
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 450 more
Conditions
Breast Cancer, Malignant Neoplasm of Breast
Interventions
Immediate Breast Reconstruction, Delayed Breast Reconstruction, Breast-Q questionnaire
Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

UV Exposure Assessed With Wearable Sensor and Sun Protection

NCT03344796
Conditions
Sunburn, Erythema, Sun Protection
Interventions
Goal attainment
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Ibrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
capecitabine, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Conditions
Cancer
Interventions
Methotrexate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 22 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
CTX-712
Drug
Lead sponsor
Chordia Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
Conditions
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions
Relugolix and Enzalutamide
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer
Interventions
Enzalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Seattle, Washington